Canada: Pharma In Brief - Federal Court Prohibits Approval Of Generic Atazanavir: Compound Patent Not Obvious

Case: Bristol-Myers Squibb Canada Co. v Teva Canada Limited, 2016 FC 580 (Court File No. T-1364-14)

Drug: REYATAZ® (atazanavir bisulfate)

Nature of case: Prohibition application pursuant to section 6 of the Patented Medicines (Notice of Compliance) Regulations, SOR/93-133 (the Regulations)

Successful party: Bristol-Myers Squibb Canada Co., Bristol-Myers Squibb Ireland, and Novartis AG (in part)

Date of decision: June 8, 2016


Bristol-Myers Squibb Canada Co. (BMS Canada) markets atazanavir bisulfate in Canada under the name REYATAZ® for the treatment of HIV. Teva Canada Limited (Teva) sought approval to market generic atazanavir capsules and alleged that two patents, listed on the patent register against REYATAZ®, were invalid. BMS Canada, together with Bristol-Myers Squibb Ireland and Novartis AG (collectively, BMS), sought an order under the Regulations prohibiting the Minister of Health (Minister) from approving Teva's generic atazanavir capsules.

The Federal Court held that Teva's anticipation and obviousness allegations regarding Canadian Patent No. 2,250,840 (the Compound Patent) were not justified and issued an order prohibiting the Minister from approving Teva's generic atazanavir capsules until the Compound Patent's expiry. The Court dismissed the application in respect of Canadian Patent No. 2,317,736 (the Salt Patent) on the basis of Teva's obviousness allegation.


The Compound Patent was filed on April 14, 1997. In this proceeding, BMS asserted two claims: one to atazanavir or a salt thereof and a second to a pharmaceutical composition of the same for treatment of a disease that is responsive to a retroviral protease.

The Salt Patent was filed on December 22, 1998. The Salt Patent contains two claims, both of which were asserted by BMS: one to atazanavir bisulfate and a second to a pharmaceutical dosage form comprising atazanavir bisulfate and a pharmaceutically acceptable carrier.

The Compound Patent claims were not obvious

Teva relied upon two documents for its obviousness allegation regarding the Compound Patent: an Australian patent application and a letter filed in the European Patent Office (EPO). Teva's expert testified that among 240 exemplified compounds, the Australian patent application specifically claimed one that would have been a "good starting point" for making atazanavir through routine modification. The promising activity of this compound, he said, was disclosed in the EPO letter.

Justice Mactavish held that Teva did not show either the EPO letter or the relevant claims of the Australian patent application to have been part of the prior art at the relevant date. Justice Mactavish also found that Teva's translation of the EPO letter from German to English was unreliable and that the EPO letter was inadmissible because it was not included in Teva's notice of allegation.

Without either document as a starting point, it would not have been more or less self-evident to a skilled person that the chemical substitutions required to make atazanavir would work, let alone result in the specific combination of advantageous properties that it possesses. Justice Mactavish found that, consistent with the inventors' course of conduct, prolonged and arduous experimentation was required to obtain the invention. It was not obvious.

The Compound Patent claims were not anticipated by a genus of billions of compounds

Teva also argued that asserted claims of the Compound Patent were anticipated by a US genus patent that disclosed billions of compounds, one of which was said to be atazanavir. BMS argued that when properly construed, atazanavir did not fall within the genus. Justice Mactavish agreed with BMS, holding that Teva's construction of the term in dispute was "nothing short of tortured." As a result, atazanavir was not disclosed, nor were its advantageous properties.

Justice Mactavish further held that a claim to a specific chemical such as atazanavir is not anticipated by a prior art reference that only teaches a broad genus of compounds, when the prior art does not provide directions that would inevitably result in the specific compound in issue. The Court also rejected Teva's argument that the Compound Patent was an invalid selection from the US genus patent.

A purposive construction of the Salt Patent

The Salt Patent claims atazanavir bisulfate as a chemical formula. Teva argued that this formula, known as "formula II" in the description, included two crystalline forms of the salt called Type-I and Type-II. Both types were exemplified as embodiments of formula II in the description. BMS argued that as written, the formula only described the Type-I salt. While the Type-I salt has the desired properties described in the Salt Patent, the Type-II salt does not. It was Teva's position that since the claims included the inoperable Type-II salt, they were invalid.

Justice Mactavish agreed with BMS that only the anhydrous Type-I salt was claimed because the formula in the claim did not show the water associated with the Type-II salt, which is a hydrate. In reaching this conclusion, the Court rejected Teva's reliance on foreign jurisprudence to the effect that a claim construction that excludes a preferred embodiment is unlikely to be correct. Although Mactavish J acknowledged it was "puzzling" that the drafters included an embodiment that was not suitable for the intended purpose of the invention, she found that the presence of this example and its reference to "formula II" was not enough to override the text of the claims.

The Salt Patent claims were obvious

On obviousness, the key issue in dispute was the extent to which the skilled person must be able to foresee the results of a "salt screen" in order for a salt to be obvious. BMS argued that before making and testing atazanavir bisulfate, it was impossible to predict whether the salt would be crystalline or have the desired combination of properties. These properties were part of the inventive concept and as a result, BMS said, the salt could not be obvious. Teva disagreed that the advantageous properties of atazanavir bisulfate formed part of the inventive concept and argued that, in any event, obtaining a suitable salt was the result of routine experimentation.

Justice Mactavish agreed with BMS that the inventive concept of the Salt Patent included the advantageous properties of atazanavir bisulfate notwithstanding the lack of supporting data in the patent, which is a question of utility rather than construction. However, the Court held that there was motivation to try to make salts of atazanavir in order to improve its oral bioavailability. The salts made in a "standard salt screen" of atazanavir would have included atazanavir bisulfate, which would then have been characterized by routine means. This was consistent with the inventors' own course of conduct, having synthesized atazanavir bisulfate on the very first day of their salt screen.

As a result the Court found the claims to atazanavir bisulfate obvious even though the salt and its advantageous properties could not have been predicted a priori. Teva's allegation was successful and the Court dismissed the application in respect of the Salt Patent.


BMS has appealed the dismissal of its application in respect of the Salt Patent (see Court File No. A-191-16).


Bristol-Myers Squibb Canada Co. v Teva Canada Limited, 2016 FC 580

About Norton Rose Fulbright Canada LLP

Norton Rose Fulbright is a global law firm. We provide the world's preeminent corporations and financial institutions with a full business law service. We have 3800 lawyers and other legal staff based in more than 50 cities across Europe, the United States, Canada, Latin America, Asia, Australia, Africa, the Middle East and Central Asia.

Recognized for our industry focus, we are strong across all the key industry sectors: financial institutions; energy; infrastructure, mining and commodities; transport; technology and innovation; and life sciences and healthcare.

Wherever we are, we operate in accordance with our global business principles of quality, unity and integrity. We aim to provide the highest possible standard of legal service in each of our offices and to maintain that level of quality at every point of contact.

For more information about Norton Rose Fulbright, see

Law around the world

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.